prodgugl.blogg.se - 0.05 mg to mcg

R 4 represents H, C 1-C 6 alkyl, Het, C 1-C 6 alkylHet, aryl or C 1-C 6 alkylaryl.

Wherein when R 2 and R 3 are present they may optionally be connected via a C-C, C-N or C-O bond Wherein when R 1 and R 2 are present they may optionally be connected via a C-C, C-N or C-O bond

R 1, R 2 and R 3 where present and attached to carbon independently represent H, halo, cyano, nitro, OR 6, OC(O)R 6, C(O)R 6, C(O)OR 6, NR 6C(O)NR 7R 8, NR 6C(O)OR 6, OC(O)NR 7R 8, C(O)NR 9R 10, NR 9R 10, SO 2NR 9R 10, SO 2R 11, C 1-C 6 alkyl, Het, C 1-C 6 alkylHet, aryl or C 1-C 6 alkylaryl.

R 1, R 2 and R 3 where present and attached to nitrogen independently represent H, C 1-C 6 alkyl, Het, C 1-C 6 alkylHet, aryl or C 1-C 6 alkylaryl.

or a pharmaceutically or veterinarily acceptable salt thereof selected from general formulae IA, IB, IC, ID and IE: According to the present invention, there is provided compounds of general formula I:

post-percutaneous transluminal coronary angioplasty (post-PTCA), peripheral vascular disease, stroke, nitrate induced tolerance, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, diseases and conditions of the eye such as glaucoma, optic neuropathy, macular degeneration, elevated intra-occular pressure, retinal or arterial occulsion and diseases characterised by disorders of gut motility, e.g. Such conditions include premature labour, dysmenorrhoea, benign prostatic hyperplasia (BPH), bladder outlet obstruction, incontinence, stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, coronary artery disease, congestive heart failure, atherosclerosis, conditions of reduced blood vessel patency, e.g.

In particular, the compounds are of value in the treatment of mammalian sexual dysfunctions such as male erectile dysfunction (MED), impotence, female sexual dysfunction (FSD), clitoral dysfunction, female hypoactive sexual desire disorder, female sexual arousal disorder, female sexual pain disorder or female sexual orgasmic dysfunction (FSOD) as well as sexual dysfunction due to spinal cord injury or selective serotonin re-uptake inhibitor (SSRI) induced sexual dysfunction but, clearly, will be useful also for treating other medical conditions for which a potent and selective cGMP PDE5 inhibitor is indicated. The compounds of the invention are of value for the curative or prophylactic treatment of mammalian sexual disorders.